You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTicagrelor
Accession NumberDB08816
TypeSmall Molecule
GroupsApproved
DescriptionTicagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
Structure
Thumb
Synonyms
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AZD 6140
AZD-6140
AZD6140
Brilinta
External Identifiers
  • AZD6140
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BrilintaTablet90 mg/1OralCardinal Health2011-08-05Not applicableUs
BrilintaTablet60 mg/1OralAstra Zeneca Pharmaceuticals Lp2015-09-04Not applicableUs
BrilintaTablet90 mg/1Oralbryant ranch prepack2011-08-05Not applicableUs
BrilintaTablet90 mg/1OralAstra Zeneca Pharmaceuticals Lp2011-08-05Not applicableUs
BrilintaTablet90 mgOralAstrazeneca Canada Inc2011-06-01Not applicableCanada
BrilintaTablet60 mgOralAstrazeneca Canada Inc2016-06-13Not applicableCanada
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated90 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
BriliqueTablet, film coated60 mgOralAstra Zeneca Ab2010-12-03Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BriliqueAstraZeneca
PossiaAstraZeneca
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIGLH0314RVC
CAS number274693-27-5
WeightAverage: 522.568
Monoisotopic: 522.186080514
Chemical FormulaC23H28F2N6O4S
InChI KeyOEKWJQXRCDYSHL-FNOIDJSQSA-N
InChI
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
IUPAC Name
(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
SMILES
CCCSC1=NC2=C(N=NN2[C@@H]2C[[email protected]](OCCO)[C@@H](O)[[email protected]]2O)C(N[C@@H]2C[[email protected]]2C2=CC(F)=C(F)C=C2)=N1
Pharmacology
IndicationFor the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.
Structured Indications
PharmacodynamicsPlasma concentrations of ticagrelor are slightly increased (12–23%) in elderly patients, women, patients of Asian ethnicity, and patients with mild hepatic impairment. They are decreased in patients that described themselves as 'coloured' and such with severe renal impairment. These differences are considered clinically irrelevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in patients with severe hepatic impairment.
Mechanism of actionLike the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19 (although it is not certain whether clopidogrel is significantly influenced by such variants).
TargetKindPharmacological actionActionsOrganismUniProt ID
P2Y purinoceptor 12Proteinyes
inhibitor
HumanQ9H244 details
Related Articles
AbsorptionAbsorbed quickly from the gut, the bioavailability being 36%.
Volume of distribution

The steady state volume of distribution of ticagrelor is 88 L.

Protein bindingBoth ticagrelor and AR-C124910XX are bound to plasma proteins (>99.7%), and both are pharmacologically active.
Metabolism

The main metabolite, AR-C124910XX, is formed quickly via CYP3A4 by de-hydroxyethylation at position 5 of the cyclopentane ring. The metabolite reaches 30–40% of ticagrelor's plasma concentrations.

Route of eliminationThe primary route of ticagrelor elimination is hepatic metabolism. When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (58% in feces, 26% in urine).
Half lifeTicagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours.
ClearanceNot Available
ToxicityBleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken. Other effects of overdose may include gastrointestinal effects (nausea, vomiting, diarrhea) or ventricular pauses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabTicagrelor may increase the anticoagulant activities of Abciximab.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ticagrelor.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Ticagrelor.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ticagrelor.Approved
AcetaminophenThe serum concentration of Ticagrelor can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Ticagrelor.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ticagrelor.Approved
AlbendazoleThe serum concentration of Ticagrelor can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Ticagrelor can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Ticagrelor can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Ticagrelor can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ticagrelor.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Ticagrelor.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Ticagrelor.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
AmantadineThe serum concentration of Ticagrelor can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ticagrelor.Approved, Investigational
Aminohippuric acidThe serum concentration of Ticagrelor can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ticagrelor.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ticagrelor.Approved
AmiodaroneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Investigational
AmitriptylineThe serum concentration of Ticagrelor can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Ticagrelor can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Ticagrelor can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Ticagrelor can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Ticagrelor.Approved
AncrodTicagrelor may increase the anticoagulant activities of Ancrod.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ticagrelor.Approved
Antithrombin III humanTicagrelor may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ticagrelor.Approved
AprepitantThe serum concentration of Ticagrelor can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Ticagrelor can be decreased when used in combination with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Ticagrelor.Experimental
ArdeparinTicagrelor may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ticagrelor.Approved, Investigational
ArgatrobanTicagrelor may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ticagrelor.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ticagrelor.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Ticagrelor.Approved
AstemizoleThe serum concentration of Ticagrelor can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Atazanavir resulting in a loss in efficacy.Approved, Investigational
AtenololThe serum concentration of Ticagrelor can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Ticagrelor can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ticagrelor.Approved, Investigational
AzelastineThe serum concentration of Ticagrelor can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ticagrelor can be increased when it is combined with Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ticagrelor.Approved, Investigational
BecaplerminTicagrelor may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BenzocaineThe serum concentration of Ticagrelor can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Ticagrelor can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Ticagrelor.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ticagrelor.Approved, Vet Approved
BexaroteneThe serum concentration of Ticagrelor can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Ticagrelor can be increased when it is combined with Biperiden.Approved
BivalirudinTicagrelor may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Boceprevir resulting in a loss in efficacy.Approved
BortezomibThe metabolism of Ticagrelor can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ticagrelor.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ticagrelor.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor.Approved
BromocriptineThe serum concentration of Ticagrelor can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ticagrelor.Approved
BuprenorphineThe serum concentration of Ticagrelor can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Ticagrelor.Approved
BuspironeThe serum concentration of Ticagrelor can be increased when it is combined with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Ticagrelor.Investigational
CabazitaxelThe serum concentration of Ticagrelor can be increased when it is combined with Cabazitaxel.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Ticagrelor.Approved
CaffeineThe serum concentration of Ticagrelor can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ticagrelor.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.Approved
CandesartanThe serum concentration of Ticagrelor can be increased when it is combined with Candesartan.Approved
CangrelorCangrelor may increase the anticoagulant activities of Ticagrelor.Approved
CaptoprilThe serum concentration of Ticagrelor can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ticagrelor.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ticagrelor.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Ticagrelor.Approved, Investigational
CaspofunginThe serum concentration of Ticagrelor can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ticagrelor.Approved, Investigational
CeritinibThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ceritinib resulting in a loss in efficacy.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ticagrelor.Withdrawn
CertoparinTicagrelor may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe serum concentration of Ticagrelor can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Ticagrelor can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Ticagrelor can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Ticagrelor can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Ticagrelor can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Ticagrelor can be increased when it is combined with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Ticagrelor.Approved
CimetidineThe serum concentration of Ticagrelor can be decreased when it is combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ticagrelor.Approved
CiprofloxacinThe serum concentration of Ticagrelor can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ticagrelor.Approved
CitalopramThe serum concentration of Ticagrelor can be increased when it is combined with Citalopram.Approved
Citric AcidTicagrelor may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
ClemastineThe metabolism of Ticagrelor can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ticagrelor.Approved, Illicit
ClofazimineThe serum concentration of Ticagrelor can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ticagrelor.Approved, Investigational
ClomipramineThe serum concentration of Ticagrelor can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ticagrelor.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ticagrelor.Approved, Nutraceutical
ClotrimazoleThe metabolism of Ticagrelor can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ticagrelor.Approved
CobicistatThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Cobicistat resulting in a loss in efficacy.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ticagrelor.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ticagrelor.Approved
ColforsinThe serum concentration of Ticagrelor can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Ticagrelor can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ticagrelor.Approved
CrizotinibThe metabolism of Ticagrelor can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Ticagrelor can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Ticagrelor can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTicagrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Ticagrelor can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Ticagrelor can be increased when it is combined with Dactinomycin.Approved
DalteparinTicagrelor may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTicagrelor may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ticagrelor.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Ticagrelor.Approved, Investigational
DarunavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Darunavir resulting in a loss in efficacy.Approved
DasatinibThe serum concentration of Ticagrelor can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Ticagrelor can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ticagrelor.Approved
DeferasiroxThe serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
DelavirdineThe metabolism of Ticagrelor can be decreased when combined with Delavirdine.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Ticagrelor.Investigational
DesipramineThe serum concentration of Ticagrelor can be increased when it is combined with Desipramine.Approved
DesirudinTicagrelor may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Ticagrelor can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Dexamethasone resulting in a loss in efficacy.Approved, Investigational, Vet Approved
DexamethasoneThe serum concentration of Ticagrelor can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranTicagrelor may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ticagrelor may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ticagrelor may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ticagrelor may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Ticagrelor can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ticagrelor.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Ticagrelor can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Ticagrelor.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ticagrelor.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ticagrelor.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ticagrelor.Approved
DihydroergotamineThe metabolism of Ticagrelor can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ticagrelor.Illicit
DiltiazemThe metabolism of Ticagrelor can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Ticagrelor.Approved
DipyridamoleThe serum concentration of Ticagrelor can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ticagrelor.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ticagrelor.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Ticagrelor.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ticagrelor.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Ticagrelor.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Ticagrelor.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ticagrelor.Approved
DoxazosinThe serum concentration of Ticagrelor can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Ticagrelor can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ticagrelor.Approved, Investigational
DoxorubicinThe serum concentration of Ticagrelor can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ticagrelor can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ticagrelor.Approved, Illicit
DronedaroneThe metabolism of Ticagrelor can be decreased when combined with Dronedarone.Approved
Edetic AcidTicagrelor may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ticagrelor.Approved
EfavirenzThe serum concentration of Ticagrelor can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Ticagrelor can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ticagrelor.Approved, Investigational
EnalaprilThe serum concentration of Ticagrelor can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxaparinTicagrelor may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Enzalutamide resulting in a loss in efficacy.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ticagrelor.Approved, Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Ticagrelor.Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Ticagrelor.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
ErgonovineThe serum concentration of Ticagrelor can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ticagrelor can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ticagrelor.Approved, Investigational
ErythromycinThe metabolism of Ticagrelor can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ticagrelor can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ticagrelor.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Ticagrelor can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Ticagrelor can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Ticagrelor can be decreased when it is combined with Estrone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ticagrelor.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ticagrelor.Approved
Ethyl biscoumacetateTicagrelor may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe metabolism of Etodolac can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Ticagrelor can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ticagrelor.Approved, Investigational
EtravirineThe serum concentration of Ticagrelor can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ticagrelor.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ticagrelor.Approved
FelodipineThe serum concentration of Ticagrelor can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Ticagrelor can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ticagrelor.Approved
FexofenadineThe serum concentration of Ticagrelor can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Ticagrelor can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ticagrelor.Approved
FluconazoleThe metabolism of Ticagrelor can be decreased when combined with Fluconazole.Approved
FluindioneTicagrelor may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ticagrelor.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ticagrelor.Approved, Illicit
FluoxetineThe serum concentration of Ticagrelor can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Ticagrelor can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Ticagrelor can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Ticagrelor can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Ticagrelor.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ticagrelor.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Ticagrelor.Approved
FluvoxamineThe metabolism of Ticagrelor can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxTicagrelor may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTicagrelor may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Ticagrelor.Approved, Investigational
FosamprenavirThe metabolism of Ticagrelor can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ticagrelor can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Fosphenytoin resulting in a loss in efficacy.Approved
Fusidic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Fusidic Acid.Approved
GabexateTicagrelor may increase the anticoagulant activities of Gabexate.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Ticagrelor.Investigational
GefitinibThe serum concentration of Ticagrelor can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ticagrelor.Approved
GenisteinThe serum concentration of Ticagrelor can be increased when it is combined with Genistein.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Ticagrelor.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Ticagrelor.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Ticagrelor.Approved
GlyburideThe serum concentration of Ticagrelor can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Ticagrelor can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Ticagrelor can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ticagrelor.Approved
GrepafloxacinThe serum concentration of Ticagrelor can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.Approved, Investigational
HaloperidolThe serum concentration of Ticagrelor can be increased when it is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Ticagrelor.Approved, Vet Approved
HeparinTicagrelor may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ticagrelor.Approved
HirulogTicagrelor may increase the anticoagulant activities of Hirulog.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Ticagrelor.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Ticagrelor.Approved, Illicit
HydrocortisoneThe serum concentration of Ticagrelor can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ticagrelor.Approved, Illicit
IbudilastIbudilast may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ticagrelor.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ticagrelor.Approved, Nutraceutical
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ticagrelor.Approved
IdelalisibThe serum concentration of Ticagrelor can be increased when it is combined with Idelalisib.Approved
idraparinuxTicagrelor may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ticagrelor.Approved, Withdrawn
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Ticagrelor.Approved
IloprostIloprost may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
ImatinibThe metabolism of Ticagrelor can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Ticagrelor can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ticagrelor.Approved
IndinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Indinavir resulting in a loss in efficacy.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Ticagrelor.Investigational
IndomethacinThe serum concentration of Ticagrelor can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Ticagrelor.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ticagrelor.Approved, Investigational
IsavuconazoniumThe metabolism of Ticagrelor can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Ticagrelor can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Itraconazole resulting in a loss in efficacy.Approved, Investigational
IvacaftorThe serum concentration of Ticagrelor can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ticagrelor can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ticagrelor.Approved
KetamineThe serum concentration of Ticagrelor can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Ticagrelor.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ticagrelor.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ticagrelor.Approved
KetoconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ketoconazole resulting in a loss in efficacy.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Ticagrelor.Approved, Vet Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ticagrelor.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ticagrelor.Approved, Investigational
LansoprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Ticagrelor can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ticagrelor.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Ticagrelor.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ticagrelor.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ticagrelor.Approved
LepirudinTicagrelor may increase the anticoagulant activities of Lepirudin.Approved
LesinuradThe metabolism of Lesinurad can be decreased when combined with Ticagrelor.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ticagrelor.Approved, Investigational
LevofloxacinThe serum concentration of Ticagrelor can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ticagrelor.Approved
LevothyroxineThe serum concentration of Ticagrelor can be decreased when it is combined with Levothyroxine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Ticagrelor.Investigational
LidocaineThe serum concentration of Ticagrelor can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ticagrelor.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ticagrelor.Approved
LiothyronineThe serum concentration of Ticagrelor can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Ticagrelor can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Ticagrelor can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ticagrelor.Approved
LoperamideThe serum concentration of Ticagrelor can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.Approved
LoratadineThe serum concentration of Ticagrelor can be increased when it is combined with Loratadine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Ticagrelor.Approved
LosartanThe serum concentration of Ticagrelor can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ticagrelor.Approved, Investigational
LuliconazoleThe serum concentration of Ticagrelor can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lumacaftor resulting in a loss in efficacy.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Ticagrelor.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ticagrelor.Approved, Investigational
MaprotilineThe serum concentration of Ticagrelor can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Ticagrelor can be increased when it is combined with Mebendazole.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Ticagrelor.Approved
MefloquineThe serum concentration of Ticagrelor can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Ticagrelor can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Ticagrelor.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ticagrelor.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ticagrelor.Investigational, Withdrawn
MeprobamateThe serum concentration of Ticagrelor can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ticagrelor.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Ticagrelor.Approved
MethadoneThe serum concentration of Ticagrelor can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ticagrelor.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ticagrelor.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ticagrelor.Approved, Vet Approved
MetoprololThe serum concentration of Ticagrelor can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Ticagrelor.Approved
MibefradilThe serum concentration of Ticagrelor can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Ticagrelor can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ticagrelor can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ticagrelor can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Ticagrelor.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ticagrelor.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Ticagrelor.Approved
MitomycinThe serum concentration of Ticagrelor can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Mitotane resulting in a loss in efficacy.Approved
MitoxantroneThe serum concentration of Ticagrelor can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ticagrelor.Approved
ModafinilThe serum concentration of Ticagrelor can be decreased when it is combined with Modafinil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Ticagrelor.Approved
MorphineThe serum concentration of Ticagrelor can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ticagrelor.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Ticagrelor.Approved
NadroparinTicagrelor may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTicagrelor may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Ticagrelor can be decreased when it is combined with Nafcillin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Ticagrelor.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ticagrelor.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ticagrelor.Approved, Vet Approved
NaltrexoneThe serum concentration of Ticagrelor can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Ticagrelor.Approved, Vet Approved
NaringeninThe serum concentration of Ticagrelor can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Ticagrelor.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Ticagrelor.Investigational
NefazodoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nefazodone resulting in a loss in efficacy.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy.Approved
NeostigmineThe serum concentration of Ticagrelor can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Ticagrelor can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nevirapine resulting in a loss in efficacy.Approved
NicardipineThe serum concentration of Ticagrelor can be increased when it is combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Ticagrelor.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Ticagrelor.Approved
NifedipineThe serum concentration of Ticagrelor can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Ticagrelor can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Ticagrelor.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ticagrelor.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ticagrelor.Approved
NisoldipineThe serum concentration of Ticagrelor can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Ticagrelor can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ticagrelor.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ticagrelor.Approved
NorethisteroneThe serum concentration of Ticagrelor can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Ticagrelor.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ticagrelor.Approved, Investigational
OlaparibThe metabolism of Ticagrelor can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Ticagrelor.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ticagrelor.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ticagrelor.Approved
OmeprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Ticagrelor.Approved
OsimertinibThe serum concentration of Ticagrelor can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Ticagrelor.Approved
OtamixabanTicagrelor may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Ticagrelor.Approved
P-NitrophenolThe serum concentration of Ticagrelor can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Ticagrelor can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Ticagrelor can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ticagrelor.Approved, Investigational
PantoprazoleThe serum concentration of Ticagrelor can be increased when it is combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ticagrelor.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Ticagrelor.Approved
ParoxetineThe serum concentration of Ticagrelor can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.Approved
PentobarbitalThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Pentobarbital resulting in a loss in efficacy.Approved, Vet Approved
Pentosan PolysulfateTicagrelor may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
PerindoprilThe serum concentration of Ticagrelor can be increased when it is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ticagrelor.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ticagrelor.Withdrawn
PhenindioneTicagrelor may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Phenobarbital resulting in a loss in efficacy.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Ticagrelor.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Ticagrelor.Approved, Vet Approved
PhenytoinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Phenytoin resulting in a loss in efficacy.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ticagrelor.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Ticagrelor.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ticagrelor.Approved
Platelet Activating FactorThe serum concentration of Ticagrelor can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ticagrelor.Approved
PosaconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Posaconazole resulting in a loss in efficacy.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Ticagrelor.Approved
PravastatinThe serum concentration of Ticagrelor can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Ticagrelor can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ticagrelor.Approved, Vet Approved
PrednisoneThe serum concentration of Ticagrelor can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Primidone resulting in a loss in efficacy.Approved, Vet Approved
ProbenecidThe serum concentration of Ticagrelor can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Ticagrelor can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Ticagrelor.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Ticagrelor.Approved, Vet Approved
PromethazineThe serum concentration of Ticagrelor can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Ticagrelor can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Ticagrelor can be increased when it is combined with Propranolol.Approved, Investigational
Protein CTicagrelor may increase the anticoagulant activities of Protein C.Approved
Protein S humanTicagrelor may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTicagrelor may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Ticagrelor can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ticagrelor.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Ticagrelor.Approved, Illicit
QuercetinThe serum concentration of Ticagrelor can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ticagrelor.Approved
QuinacrineThe serum concentration of Ticagrelor can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Ticagrelor can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Ticagrelor can be increased when it is combined with Quinine.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ticagrelor.Investigational
RanitidineThe serum concentration of Ticagrelor can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ticagrelor.Approved, Investigational
ReboxetineThe serum concentration of Ticagrelor can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ticagrelor can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Ticagrelor can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Ticagrelor.Experimental, Investigational
ReviparinTicagrelor may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Ticagrelor.Approved
RifabutinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Rifabutin resulting in a loss in efficacy.Approved
RifampicinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Rifampicin resulting in a loss in efficacy.Approved
RifapentineThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Rifapentine resulting in a loss in efficacy.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ticagrelor.Approved, Investigational
RilpivirineThe serum concentration of Ticagrelor can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ticagrelor.Approved, Investigational
RitonavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ritonavir resulting in a loss in efficacy.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ticagrelor.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ticagrelor.Investigational, Withdrawn
RolapitantThe serum concentration of Ticagrelor can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ticagrelor.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Ticagrelor.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Ticagrelor.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ticagrelor.Approved, Vet Approved
SaquinavirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Saquinavir resulting in a loss in efficacy.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Ticagrelor.Investigational
ScopolamineThe serum concentration of Ticagrelor can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Ticagrelor can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ticagrelor.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ticagrelor.Approved, Investigational
SertralineThe serum concentration of Ticagrelor can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Ticagrelor.Approved, Vet Approved
SildenafilThe metabolism of Ticagrelor can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ticagrelor.Approved
SiltuximabThe serum concentration of Ticagrelor can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ticagrelor can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ticagrelor.Approved
SirolimusThe serum concentration of Ticagrelor can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ticagrelor.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ticagrelor.Approved
SorafenibThe serum concentration of Ticagrelor can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ticagrelor.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ticagrelor.Experimental
SpironolactoneThe serum concentration of Ticagrelor can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Ticagrelor.Investigational
St. John's WortThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with St. John's Wort resulting in a loss in efficacy.Nutraceutical
StaurosporineThe serum concentration of Ticagrelor can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Ticagrelor can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Ticagrelor can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ticagrelor.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ticagrelor.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Ticagrelor.Approved
SulfinpyrazoneThe serum concentration of Ticagrelor can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Ticagrelor can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideTicagrelor may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Ticagrelor can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Ticagrelor can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Ticagrelor.Approved, Withdrawn
TacrineThe serum concentration of Ticagrelor can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Ticagrelor can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Ticagrelor can be decreased when it is combined with Tamoxifen.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Ticagrelor.Approved
Taurocholic AcidThe serum concentration of Ticagrelor can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ticagrelor.Approved
TelaprevirThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telaprevir resulting in a loss in efficacy.Approved
TelithromycinThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Telithromycin resulting in a loss in efficacy.Approved
TelmisartanThe serum concentration of Ticagrelor can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Ticagrelor.Approved
TemsirolimusThe serum concentration of Ticagrelor can be increased when it is combined with Temsirolimus.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Ticagrelor.Approved
TerazosinThe serum concentration of Ticagrelor can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ticagrelor.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Ticagrelor can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Ticagrelor can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ticagrelor can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ticagrelor.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Ticagrelor.Approved, Vet Approved
TiclopidineThe metabolism of Ticagrelor can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Ticagrelor.Approved
TirofibanTirofiban may increase the anticoagulant activities of Ticagrelor.Approved
TocilizumabThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Ticagrelor.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Ticagrelor.Approved, Investigational
TolvaptanThe serum concentration of Ticagrelor can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ticagrelor.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Ticagrelor.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ticagrelor.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Ticagrelor.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Ticagrelor.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ticagrelor.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ticagrelor.Approved
TrazodoneThe serum concentration of Ticagrelor can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Ticagrelor.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ticagrelor.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Ticagrelor can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Ticagrelor can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Ticagrelor.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ticagrelor.Approved
TrimethoprimThe serum concentration of Ticagrelor can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Ticagrelor can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Ticagrelor.Withdrawn
TroleandomycinThe serum concentration of Ticagrelor can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ticagrelor.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ticagrelor.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ticagrelor.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Ticagrelor.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Ticagrelor.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ticagrelor.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ticagrelor.Approved
VenlafaxineThe metabolism of Ticagrelor can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ticagrelor can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ticagrelor.Investigational
VinblastineThe serum concentration of Ticagrelor can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ticagrelor.Approved, Investigational
VincristineThe serum concentration of Ticagrelor can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Ticagrelor can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ticagrelor.Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Ticagrelor.Approved
VoriconazoleThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Voriconazole resulting in a loss in efficacy.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Ticagrelor.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Ticagrelor.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
Ym150Ticagrelor may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ticagrelor.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ticagrelor.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Ticagrelor.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ticagrelor.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Ticagrelor.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Ticagrelor can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ticagrelor can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ticagrelor.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Ticagrelor.Approved
Food InteractionsNot Available
References
Synthesis Reference

Anil Shahaji Khile, “NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR.” U.S. Patent US20130165696, issued June 27, 2013.

US20130165696
General ReferencesNot Available
External Links
ATC CodesB01AC24
AHFS Codes
  • 20:12:18
PDB EntriesNot Available
FDA labelDownload (1.21 MB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier-0.6719
Caco-2 permeable-0.5989
P-glycoprotein substrateSubstrate0.7626
P-glycoprotein inhibitor INon-inhibitor0.5907
P-glycoprotein inhibitor IINon-inhibitor0.9617
Renal organic cation transporterNon-inhibitor0.8606
CYP450 2C9 substrateNon-substrate0.7734
CYP450 2D6 substrateNon-substrate0.8048
CYP450 3A4 substrateSubstrate0.5057
CYP450 1A2 substrateNon-inhibitor0.5372
CYP450 2C9 inhibitorNon-inhibitor0.5767
CYP450 2D6 inhibitorNon-inhibitor0.8016
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.8744
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6243
Ames testNon AMES toxic0.5075
CarcinogenicityNon-carcinogens0.7777
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6308 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7742
hERG inhibition (predictor II)Non-inhibitor0.5914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral60 mg
TabletOral60 mg/1
TabletOral90 mg/1
TabletOral90 mg
Tablet, film coatedOral60 mg
Tablet, film coatedOral90 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2296665 No2008-06-102018-07-15Canada
CA2351709 No2010-04-062019-12-02Canada
CA2408596 No2010-12-212021-05-31Canada
US6251910 No1998-07-152018-07-15Us
US6525060 No1999-12-022019-12-02Us
US7250419 No1999-12-022019-12-02Us
US7265124 No2001-07-092021-07-09Us
US8425934 No2010-04-172030-04-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility10 μg/mLFDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.063 mg/mLALOGPS
logP2.31ALOGPS
logP2.28ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)2.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area138.44 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity142.13 m3·mol-1ChemAxon
Polarizability51.27 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as triazolopyrimidines. These are polycyclic aromatic compounds containing triazole ring fused to a pyrimidine ring. Triazole is a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTriazolopyrimidines
Sub ClassNot Available
Direct ParentTriazolopyrimidines
Alternative Parents
Substituents
  • Triazolopyrimidine
  • Alkylarylthioether
  • Secondary aliphatic/aromatic amine
  • Halobenzene
  • Fluorobenzene
  • Aminopyrimidine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Cyclopentanol
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,3-triazole
  • Triazole
  • Cyclic alcohol
  • Azole
  • Secondary alcohol
  • 1,2-diol
  • Azacycle
  • Sulfenyl compound
  • Thioether
  • Secondary amine
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.
Gene Name:
P2RY12
Uniprot ID:
Q9H244
Molecular Weight:
39438.355 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Teng R, Oliver S, Hayes MA, Butler K: Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. doi: 10.1124/dmd.110.032250. Epub 2010 Jun 15. [PubMed:20551239 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on August 01, 2011 15:32 / Updated on December 08, 2016 02:39